Phase 1 — Recheck the Phenotype
Reassess CAP/HAP/VAP timing, aspiration risk, viral disease, immunocompromise, necrotizing/cavitary disease and noninfectious mimics such as edema, hemorrhage, organizing inflammation or pulmonary embolism.
A progressive bedside problem for apparent pneumonia with persistent hypoxemia, fever or shock despite initial therapy.
Failure to improve should trigger diagnostic reassessment rather than automatic antibiotic broadening. Confirm that the syndrome is pneumonia, reconsider the host and exposure context, and look for complications or a source that requires a procedure.
Reassess CAP/HAP/VAP timing, aspiration risk, viral disease, immunocompromise, necrotizing/cavitary disease and noninfectious mimics such as edema, hemorrhage, organizing inflammation or pulmonary embolism.
Review specimen quality, prior antibiotics, cultures and local resistance. Use invasive sampling selectively when it is likely to change management rather than as a routine reflex.
Use imaging and bedside assessment to look for empyema, abscess/necrosis, airway obstruction or another source of sepsis. Drainage or other source control may matter more than broader antibiotics.
Evidence status
Review metadata not yet recorded.
Status, review dates and guideline versions appear here once editorial metadata is authored for this content.
From initial noninvasive modality selection to ROX index tracking and timely intubation triggers.
From confirming true hypoxemia to identifying the underlying mechanism.
From SSC 2026 infection-likelihood/shock-based early treatment and source control to reassessment, de-escalation, and fluid stewardship.
From recognizing organ dysfunction to source identification and time-sensitive empiric therapy.
Pattern-based ICU pneumonia approach: severe CAP, HAP/VAP, aspiration, viral, necrotizing, immunocompromised and nonresolving pneumonia.
IDSA/ATS severe CAP criteria, rapid microbiology, targeted empiric antimicrobial regimens, and landmark adjunctive hydrocortisone evidence (CAPE COD).
Quantitative lower tract sampling (ETA vs BAL), rapid multiplex PCR panels and stewardship interpretation, PK/PD extended beta-lactams, 7-day duration, and the SHEA prevention bundle.
Diagnosis and source control of complicated parapneumonic effusion and empyema with drainage, tPA/DNase and surgical escalation
Safe diagnostic and therapeutic bronchoscopy in hypoxemic, mechanically ventilated and bleeding ICU patients